RTTNews | Sep 10, 2021 10:19AM EDT

10:19 Friday, September 10, 2021 (RTTNews.com) - Shares of IVERIC bio, Inc. (ISEE) surged over 60% on Friday morning despite no statement from the company to drive the shares. However, IVERIC's stock must have benefited from the news that its rival, Apellis Pharmaceuticals' (APLS) Phase 3 study of eye disease treatment failed to meet its primary endpoint.

ISEE is currently trading at $14.02, up $5.33 or 61.33%, on the Nasdaq, while APLS is currently trading at $31.46, down $24.15 or 43.43%.

IVERIC bio is a biopharmaceutical company that develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases.

Apellis Pharmaceuticals announced that DERBY study of Pegcetacoplan for geographic atrophy or GA failed to meet the primary endpoint.

Read the original article on RTTNews ( https://www.rttnews.com/3224853/why-are-iveric-bio-shares-surging-over-60.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved